公开(公告)号：US20110166067A1

公开(公告)日：2011-07-07

申请号：US13003760

申请日：2008-12-11

Applicant: Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

Inventor： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

IPC: A61K38/18 ,  C07K14/495 ,  A61P17/02 ,  A61P9/00

CPC classification number: A61K38/1841

Abstract: The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-β3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-β3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.

Abstract translation: 本发明提供使用TGF-β3抑制人类瘢痕形成的新治疗方法，以及用于抑制人瘢痕形成的新用途的TGF-β3。 在治疗的第一次发生中，TGF-β1被提供给每个厘米的伤口边缘或每厘米的伤口以第一治疗有效量形成的部位; 并且在随后的治疗发生中，在更大的治疗有效量的TGF-βb中，向伤口边缘的每厘米提供TGF-β; 3。 治疗的发生发生在彼此之间8小时至48小时之间。 TGF-β可以通过皮内注射来提供。 还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。